@article{APS4599,
author = {Xi Hu and Ying Feng and Yu Shen and Xiao-feng Zhao and Juan-hong Yu and Yu-she Yang and Ying Leng},
title = {Antidiabetic effect of a novel non-thiazolidinedione PPAR big gamma/alpha agonist on ob/ob mice},
journal = {Acta Pharmacologica Sinica},
volume = {27},
number = {10},
year = {2016},
keywords = {},
abstract = {Aim: To study whether T33, a new synthesized non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR) gamma/alpha dual agonist has an antidiabetic effect on ob/ob mice.
Methods: Ob/ob mice were treated with 4 mg/kg or 8 mg/kg T33 by gavage for 20 d. Blood glucose levels were measured regularly. An oral glucose tolerance test (OGTT) and an insulin tolerance test (ITT) were preformed on d 8 and d 12, respectively. The levels of insulin, triglyceride and free fatty acid (FFA) in the serum were measured at the end of administration. The intramuscular and liver triglyceride content was also determined.
Results: T33 reduced the hyperglycemia, hyperinsulinemia and hyperlipidemia of the ob/ob mice. The OGTT and ITT showed that the insulin resistance state of the ob/ob mice was obviously ameliorated after T33 treatment. After 20 d treatment with 8 mg/kg T33, the triglyceride content in the gastrocnemius muscle decreased significantly. T33 did not have any effect on triglyceride content in the liver, whereas rosiglitazone significantly increased the hepatocyte lipid deposition.
Conclusion: The PPARgamma/alpha dual agonist T33 has antidiabetic and insulin-sensitizing effects in ob/ob mice. It has the potential to be a new therapeutic candidate for the treatment of type 2 diabetes.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/4599}
}